Nordic Nanovector stock has been consolidating upon positive news about FDA Fast Track Status for Betalutin and amended patient eligibility criteria in the PARADIGME clinical trial, and looks set to draw a golden cross for the first time since the pre ASH rally of 2018.
Entrys should be made with keen eyes on risk management, but it is nice to see some good...
